Search Login Register

Juvenile Xanthogranuloma Summary

Description: Benign disorder of infants and children caused by proliferation of HISTIOCYTES, macrophages found in tissues. These histiocytes, usually lipid-laden non-Langerhans cells, form multiple yellow-red nodules most often in the skin, the eye, and sometimes in the viscera. Patients appear to have normal lipid metabolism and are classified as a normolipemic non-Langerhans cell histiocytosis.

Also Known As: Xanthogranuloma, Juvenile; Juvenile Xanthogranulomas; Juvenile Xanthoma; Juvenile Xanthomas; Nevoxanthoendotheliomas Show All >>

Networked: 75 relevant articles (4 outcomes, 1 trials/studies) for this Disease

Key Drugs and Agents for Juvenile Xanthogranuloma

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. Cladribine : 2 outcomes in 3 results : FDA 3 Generic
  2. Triamcinolone Acetonide (Azmacort) : 1 outcome in 1 result : FDA 135 Generic
  3. Dermatofibrosarcoma protuberans : 1 study in 5 results : IBA
  4. S100 Proteins (S 100 Protein) : 6 results : IBA
  5. Steroids : 5 results : IBA
  6. Factor XIIIa : 4 results : IBA
  7. Antigens : 4 results : IBA
  8. Muramidase (Lysozyme) : 3 results : IBA
  9. Cholestanol (Coprostanol) : 3 results : IBA
  10. Cholesterol : 3 results : IBA
Show All >>

Diseases Related to Juvenile Xanthogranuloma

  1. Langerhans-Cell Histiocytosis (Histiocytosis, Langerhans Cell)
  2. Erdheim-Chester Disease
  3. Benign Fibrous Histiocytoma (Dermatofibroma)
  4. Malignant Fibrous Histiocytoma
  5. Neoplasms (Cancer)
Show All >>

Key Therapies for Juvenile Xanthogranuloma

Efficacy Chart >>
  1. X-Ray Therapy : 1 outcome in 1 result
  2. Radiotherapy : 5 results
  3. Drug Therapy (Chemotherapy) : 5 results
  4. Salvage Therapy : 2 results
  5. Curettage : 2 results
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.